First pan FGFR kinase inhibitor to be approved in the European Economic Area, for adults with unresectable or metastatic urothelial carcinoma and susceptible FGFR3 alterations Approval based on THOR results, showing 36 percent reduction in risk of death with erdafitinib versus chemotherapy1 BEERSE, BELGIUM, Aug. 23, 2024 (GLOBE NEWSWIRE) — Janssen-Cilag International NV, a Johnson […]
Category Archives: Pr Newswire
23
Aug
Aug
LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA […]
Pr Newswire
XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders
23
Aug
Aug
CALGARY, Alberta, Aug. 23, 2024 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the management information circular (the “Circular”) for the annual and special meeting (the […]
SHANGHAI, Aug. 23, 2024 /PRNewswire/ — GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced China’s National Medical Products Administration has approved Dupert®（fulzerasib, GFH925/IBI351）for the treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring KRAS G12C mutation who have received at least one systemic therapy. Fulzerasib was the […]
HO CHI MINH CITY, Vietnam, Aug. 23, 2024 /PRNewswire/ — The International Travel Expo Ho Chi Minh City (ITE HCMC 2024) is set to become one of Asia’s most influential travel expos, driven by participation from leading global organizations and businesses, increased attention from prestigious international media, and continuous enhancements to its International Hosted Buyer […]
Q2 2024 Financial Highlights： Revenue was RMB 8.64 billion, an increase of 36.9% year-on-year and 26.3% quarter-on-quarter. A record high Q2 in the company’s history. Generated RMB 1.65 billion cash from operations. With net capex investments of RMB 0.93 billion, free cash flow for the quarter was RMB 0.72 billion. Net profit attributable to owners […]
HONG KONG, Aug. 23, 2024 /PRNewswire/ — The 10th edition of GS1 Hong Kong Food Safety Forum concluded successfully today, drawing more than 200 attendees from the food and catering industry to join in-person. Ms. Diane Wong, Under Secretary for Environment and Ecology of the HKSAR Government, kick-started the event as the Guest of Honour. […]
The World’s First-in-Class Intrauterine Drug-Eluting System SHANGHAI, Aug. 23, 2024 /PRNewswire/ — Corina Intrauterine Drug-Eluting System (“Corina”), developed by Yipurun (Shanghai) Biotechnology Co., Ltd. (“YPR”), has received approval in China (G.X.Z.Z. 20243181461) for use in patients with moderate-to-severe intrauterine adhesions (IUA) who undergo transcervical resection of adhesions (TCRA). The approval for this indication is based on a […]
23
Aug
Aug
SANTA ANA, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), today announced it received a standard notice (the “Notice”) on August 20, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) […]
Pr Newswire
Ovarian Cancer Canada announces its annual Walk of Hope to support Canadians facing ovarian cancer
23
Aug
Aug
Join or donate to one of the 31 walks across Canada on September 8, visit www.ovariancancerwalkofhope.ca TORONTO, Aug. 22, 2024 (GLOBE NEWSWIRE) — Held annually during Ovarian Cancer Awareness Month in September, Ovarian Cancer Canada’s Walk of Hope raises vital funds to power ovarian cancer research, provide education and resources, and fuel advocacy efforts across […]